Tokyo-based Daiichi Sankyo Co. opened a clinical trial for ... Other Japanese drugmakers are trying to develop their own COVID-19 vaccines, again with no prospects in sight for their practical ...

Keeping a lid on drug prices is proving costly for ambitions to turn the UK into a life sciences superpower ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

We take a look at the company's story, from its creation as a merger of two equals, to its recent major restructuring and its drives in cutting-edge oncology and COVID-19. In 1998, Europe’s ...

A nasal COVID-19 vaccine developed at WashU is set for U.S. clinical trials after FDA approval. The vaccine, administered via nasal spray or inhalation, could not only prevent severe illness but also ...

The study is sponsored by AstraZeneca (LSE/STO/Nasdaq:AZN) in collaboration with Daiichi Sankyo (TSE: 4568). We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this ...

To recap, NTK in October 2023 filed a lawsuit in the Tokyo District Court alleging that Daiichi Sankyo caused losses by preventing NTK from proceeding with open offers to buy a stake in Indian ...

KUALA LUMPUR: IHH Healthcare Bhd ’s unit is seeking compensation ranging from 4.24 billion rupees (RM200mil) to 109.3 billion rupees (RM5.7bil) from Japan's Daiichi Sankyo for its stake purchase ...

Malaysia's IHH Healthcare said on Thursday its unit is seeking compensation of up to 109.3 billion rupees ($1.25 billion) from Japan's Daiichi Sankyo for its stake buy in India's Fortis Healthcare.

PETALING JAYA: IHH Healthcare Bhd says its unit is seeking compensation of up to 109.3 billion rupees (RM5.46bil) from Japan’s Daiichi Sankyo for its stake buy in India’s Fortis Healthcare.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...